http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Positive Top-line Results of Pfizer’s Phase 3 Study Exploring Coadministration of Prevnar 20™ With Seasonal Flu Vaccine in Older Adults Released
-
Pfizer (PFE), BioNTech (BNTX) Submit Initial Data to U.S. FDA From Pivotal Trial of COVID-19 Vaccine in Children 5 to <12 Years of Age
-
Pfizer and BioNTech Submit Initial Data to U.S. FDA From Pivotal Trial of COVID-19 Vaccine in Children 5 to <12 Years of Age
-
Valneva and Pfizer Report Further Positive Phase 2 Results, Including Booster Response, for Lyme Disease Vaccine Candidate
-
Pfizer (PFE) Commences Study of mRNA-Based Flu Vaccine Program
-
Pfizer Starts Study of mRNA-Based Next Generation Flu Vaccine Program
-
Pfizer (PFE) Commences Global Phase 2/3 EPIC-PEP Study of Novel COVID-19 Oral Antiviral Candidate for Post-Exposure Prophylaxis in Adults
-
Pfizer Starts Global Phase 2/3 EPIC-PEP Study of Novel COVID-19 Oral Antiviral Candidate for Post-Exposure Prophylaxis in Adults
-
OPKO Health (OPK) and Pfizer (PFE) Extend U.S. FDA Review of Biologics License Application of Somatrogon for Pediatric Growth Hormone Deficiency
-
Pfizer and OPKO Announce Extension of U.S. FDA Review of Biologics License Application of Somatrogon for Pediatric Growth Hormone Deficiency
-
Pfizer Invites Public to View and Listen to Webcast of Pfizer November 2 Conference Call with Analysts
-
Pfizer Declares Fourth-Quarter 2021 Dividend
-
Pfizer (PFE) and BioNTech SE (BNTX) Announce FDA Emergency Use Authorization of COVID-19 Vaccine Booster
-
Pfizer (PFE) and BioNTech SE (BNTX) Announce FDA Emergency Use Authorization of COVID-19 Vaccine Booster
-
Pfizer and BioNTech Receive First U.S. FDA Emergency Use Authorization of a COVID-19 Vaccine Booster
-
Pfizer (PFE), BioNTech (BNTX) in Collaboration with U.S. to Provide 500M Additional COVID-19 Vaccine Doses to Poor Nations
-
Pfizer and BioNTech Expand Collaboration with U.S. to Provide 500 Million Additional COVID-19 Vaccine Doses at Not-for-Profit Price for Donation to Poorest Countries
-
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
-
Pfizer (PFE), BioNTech (BNTX) Announce Positive Topline Results From Pivotal Trial of COVID-19 Vaccine in Children 5 to 11 Years
-
Pfizer and BioNTech Announce Positive Topline Results From Pivotal Trial of COVID-19 Vaccine in Children 5 to 11 Years
-
FDA Advisory Committee Votes Unanimously in Favor of COMIRNATY® Booster for Emergency Use in People 65 and Older and Certain High-Risk Populations
-
FDA Advisory Committee Votes Unanimously in Favor Of COMIRNATY® Booster for Emergency Use in People 65 and Older and Certain High-risk Populations
-
Myovant Sciences (MYOV), Pfizer (PFE) Announce FDA Acceptance of sNDA for MYFEMBREE for Management of Moderate to Severe Pain Associated With Endometriosis
-
Myovant Sciences and Pfizer Announce FDA Acceptance of Supplemental New Drug Application for MYFEMBREE® for the Management of Moderate to Severe Pain Associated With Endometriosis
-
Myovant Sciences and Pfizer Announce FDA Acceptance of Supplemental New Drug Application for MYFEMBREE® for the Management of Moderate to Severe Pain Associated With Endometriosis
-
Pfizer (PFE) Announces UK’s MHRA Grants Marketing Authorisation for CIBINQO for Adults and Adolescents With Moderate to Severe Atopic Dermatitis
-
UK’s MHRA Grants Marketing Authorisation for Pfizer’s CIBINQO® (abrocitinib) for Adults and Adolescents With Moderate to Severe Atopic Dermatitis
-
Pfizer Invites Public to Listen to Two Webcasts of Pfizer Discussions at Upcoming Healthcare Conferences
-
Pfizer (PFE) Initiates Phase 3 Trial for Investigational Vaccine Against RSV
-
Pfizer Announces Start of Phase 3 Clinical Trial in Adults for Its Investigational Vaccine Against Respiratory Syncytial Virus (RSV)
-
Pfizer (PFE) Announces Positive Results from Phase 3 JADE DARE Trial Comparing the Efficacy of Abrocitinib and Dupilumab for Moderate to Severe Atopic Dermatitis
-
Positive Top-Line Results From Pfizer’s Phase 3 JADE DARE Trial Comparing the Efficacy of Abrocitinib and Dupilumab for Moderate to Severe Atopic Dermatitis
-
Pfizer (PFE) Appoints Aamir Malik as Chief Business Innovation Officer
-
Pfizer Announces New Chief Business Innovation Officer
-
Pfizer (PFE) and BioNTech(BTNX) Partner With Eurofarma Laboratórios to Manufacture COVID-19 Vaccine in Latin America
-
Pfizer and BioNTech Announce Collaboration with Brazil’s Eurofarma to Manufacture COVID-19 Vaccine Doses for Latin America
-
Pfizer and BioNTech Announce Collaboration With Brazil’s Eurofarma to Manufacture COVID-19 Vaccine Doses for Latin America
-
Pfizer and BioNTech Initiate Rolling Submission of Supplemental Biologics License Application to U.S. FDA for Booster Dose of COMIRNATY® in Individuals 16 and Older
-
Pfizer (PFE), BioNTech (BNTX) Confirm Rolling Submission of sBLA to U.S. FDA for Booster Dose of Covid-19 Vaccine
-
Pfizer and BioNTech Initiate Rolling Submission of Supplemental Biologics License Application to U.S. FDA for Booster Dose of COMIRNATY® in Individuals 16 and Older
-
Pfizer (PFE), BioNTech SE (BNTX) Confirm Full U.S. FDA Approval for COVID-19 Vaccine
-
Pfizer-BioNTech COVID-19 Vaccine COMIRNATY® Receives Full U.S. FDA Approval for Individuals 16 Years and Older
-
Pfizer-BioNTech COVID-19 Vaccine COMIRNATY® Receives Full U.S. FDA Approval for Individuals 16 Years and Older
-
Trillium Therapeutics (TRIL) Acquired by Pfizer (PFE) for $2.26B or $18.50/sh
-
Pfizer to Acquire Trillium Therapeutics Inc.
-
Pfizer to Acquire Trillium Therapeutics Inc.
-
Pfizer's (PFE) XELJANZ Receives Marketing Authorization in European Union for Treatment of Active Polyarticular Juvenile Idiopathic Arthritis and Juvenile Psoriatic Arthritis
-
XELJANZ® (tofacitinib citrate) Receives Marketing Authorization in the European Union for the Treatment of Active Polyarticular Juvenile Idiopathic Arthritis and Juvenile Psoriatic Arthritis
-
Pfizer (PFE), BioNTech (BNTX) Announce Submission of Initial Data to U.S. FDA to Support Booster Dose of COVID-19 Vaccine
-
Pfizer and BioNTech Announce Submission of Initial Data to U.S. FDA to Support Booster Dose of COVID-19 Vaccine

